The 21-gene recurrence score is a genetic assay developed to estimate the likelihood of distant recurrence in patients with oestrogen-receptor-positive, lymph-node-negative breast cancer treated with adjuvant endocrine therapy. Now, two studies explore how the 21-gene recurrence score has been used to inform treatment decisions in this setting and beyond.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Paik, S. et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24, 3726–3724 (2006).
Sparano, J. A. et al. Prospective validation of a 21-gene expression assay in breast cancer. N. Engl. J. Med. 373, 2005–2014 (2015).
King, T. A. et al. Prognostic impact of 21-gene recurrence score in patients with stage IV breast cancer: TBCRC 013. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2015.63.1960 (2016).
Jasem, J. et al. 21-gene recurrence score assay as a predictor of adjuvant chemotherapy administration for early-stage breast cancer: an analysis of use, therapeutic implications, and disparity profile. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2015.65.0887 (2016).
Cardoso, F. et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast 23, 489–502 (2014).
Filipits, M. et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin. Cancer Res. 17, 6012–6020 (2011).
Gnant, M. et al. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathologic risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann. Oncol. 25, 339–345 (2014).
Piccart, M. et al. Primary analysis of the EORTC 10041/ BIG 3-04 MINDACT study: a prospective, randomized study evaluating the clinical utility of the 70-gene signature (MammaPrint) combined with common clinical-pathological criteria for selection of patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes. Presented at the American Association of Cancer Research Annual Meeting, New Orleans, Louisiana, USA http://webcast.aacr.org/p/2016annual/8037 (2016).
Harris, L. et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage breast invasive breast cancer: American Society of Clinical Oncology Practice Guideline. J. Clin. Oncol. 34, 1134–1150 (2016).
Klein, M. E. et al. Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis. Mod. Pathol. 26, 658–664 (2013).
Acknowledgements
N.E.D. receives support from the Breast Cancer Research Foundation and the National Institutes of Health (grant P30-CA047904).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Puhalla, S., Davidson, N. The 21-gene recurrence score — biology remains at the forefront. Nat Rev Clin Oncol 13, 470–472 (2016). https://doi.org/10.1038/nrclinonc.2016.98
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2016.98
